Virion Systems

Virion Systems is a biopharmaceutical company specializing in the development of therapies for infectious diseases, with a landmark focus on respiratory syncytial virus (RSV). The company is best known for its foundational research that led to the development of RespiGam, the first FDA-approved prophylactic for RSV, and its significant contributions to the development of the monoclonal antibody Synagis (palivizumab). Based in Gaithersburg, Maryland, Virion Systems utilizes specialized animal models, particularly the cotton rat, to study viral pathogenesis and evaluate potential immunotherapies. The firm's expertise spans clinical virology and immunology, focusing on protecting high-risk infants and other vulnerable populations from severe viral respiratory infections. As a private research-driven entity, Virion Systems continues to leverage its intellectual property and deep domain knowledge to advance the field of pediatric infectious disease prevention.